# US 2016/0237092 A1 · Pharmaceutical compositions comprising perillyl alcohol derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0237092 A1
- Document ID: US20160237092A1
- Status: Published application
- Kind: A1
- Application number: 15/041,743
- Filed: 2016-02-11
- Published: 2016-08-18
- Earliest claimed: 2015-02-12
- Assignees: NeOnc Technologies, Inc.
- Applicants: Neonc Technologies Inc.
- Inventors: Thomas Chen; Daniel Levin; Satish Pupalli
- Web page: https://patentgrep.com/patent/US20160237092A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 253/075: Two hetero atoms, in positions 3 and 5
- C07D 493/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

## Claims

### Claim 1

A compound of the Formula I;
wherein R is selected from the group consisting of a C4 to C28 linear or branched alkyl, linear or branched C4 to C28 alkeneyl and a linear or branched C4 to C28 alkynyl group; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein R is a C4 to C28 linear or branched alkeneyl containing 1, 2, 3, 4 or 5 double bonds or a linear or branched C4 to C28 alkynyl group containing 1, 2, 3, 4 or 5 triple bonds.

### Claim 3 (depends on 1)

The compound according to claim 1 of the Formula II;
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1, 2, 3)

A method for treating a disease in a mammal, comprising the step of delivering to the mammal a therapeutically effective amount of the compound according to claim 1, 2 or 3.

### Claim 5 (depends on 4)

The method of claim 4, wherein the disease is cancer.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cancer is a tumor of the nervous system.

### Claim 7 (depends on 6)

The method of claim 6, wherein the tumor is a glioblastoma.

### Claim 8 (depends on 5)

The method of claim 5, wherein the cancer is a skin cancer selected from the group of melanoma, basal cell carcinoma, and squamous cell carcinoma.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cancer is melanoma.

### Claim 10 (depends on 9)

The method of claim 9, wherein the disease is a precancerous skin lesion.

### Claim 11 (depends on 4)

The method of claim 4, wherein the compound is administered by inhalation, intranasally, orally, intravenously, topically, transdermally, subcutaneously or intramuscularly.

### Claim 12 (depends on 11)

The method of claim 11, wherein the composition is administered topically.

### Claim 13 (depends on 1, 2, 3)

A pharmaceutical composition comprising a compound according to claim 1, 2 or 3.

### Claim 14

A compound of the Formula III;
wherein R1 is selected from a C4 to C28 linear or branched alkyl, linear or branched C4 to C28 alkeneyl or a linear or branched C4 to C28 alkynyl group; or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

The compound according to claim 14 wherein R1 is a C4 to C28 linear or branched alkeneyl containing 1, 2, 3, 4 or 5 double bonds or a linear or branched C4 to C28 alkynyl group containing 1, 2, 3, 4 or 5 triple bonds.

### Claim 16 (depends on 14)

The compound according to claim 14 of the Formula IV; or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 14, 15, 16)

A method for treating a disease in a mammal, comprising the step of delivering to the mammal a therapeutically effective amount of the compound according to claim 14, 15 or 16.

### Claim 18 (depends on 17)

The method of claim 17, wherein the disease is cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the cancer is a tumor of the nervous system.

### Claim 20 (depends on 19)

The method of claim 19, wherein the tumor is a glioblastoma.

### Claim 21 (depends on 18)

The method of claim 18, wherein the cancer is a skin cancer selected from the group of melanoma, basal cell carcinoma, and squamous cell carcinoma.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cancer is melanoma.

### Claim 23 (depends on 22)

The method of claim 22, wherein the disease is a precancerous skin lesion.

### Claim 24 (depends on 14)

The method of claim 14, wherein the compound is administered by inhalation, intranasally, orally, intravenously, topically, transdermally, subcutaneously or intramuscularly.

### Claim 25 (depends on 24)

The method of claim 24, wherein the composition is administered topically.

### Claim 26 (depends on 14, 15, 16)

A pharmaceutical composition comprising a compound according to claim 14, 15 or 16.

### Claim 27

A process for making a compound of the Formula I
comprising the steps of
a) reacting Temozolamide with oxalyl chloride in a halogenated solvent to give the isocyanate of Temozolamide Formula A
b) reacting the isocyanate of Temozolamide with perillyl alcohol in a halogenated solvent to afford a compound of Formula B
c) reacting the compound of Formula B with an acid chloride of the Formula C
wherein R is selected from the group consisting of a C4 to C28 linear or branched alkyl, linear or branched C4 to C28 alkeneyl containing 1, 2, 3, 4, or 5 double bonds or a linear or branched C4 to C28 alkynyl group; containing 1, 2, 3, 4 or 5 triple bonds in the presence of a base in an ethereal solvent to afford a compound of the Formula I.

### Claim 28 (depends on 27)

The process according to claim 27 wherein the halogenated solvent is 1,2 dichloroethane.

### Claim 29 (depends on 27)

The process according to claim 27 wherein the acid chloride is linoleic acid chloride.

### Claim 30 (depends on 27)

The process according to claim 27 wherein the base is NaH.

### Claim 31 (depends on 27)

The process according to claim 27 wherein the ethereal solvent is THF.
